XtalPi
@xtalpi.bsky.social
Accelerating molecular discovery with AI and automation.
Most #HIV drugs stop the virus after it is already inside the cell. A small molecule that stops it at the door is a different bet, and a harder one.
Viva-Thera, which we incubated, has nominated a preclinical candidate against that entry machinery in 7 months.
The target: MPER
Viva-Thera, which we incubated, has nominated a preclinical candidate against that entry machinery in 7 months.
The target: MPER
September 23, 2026 at 9:30 AM
Most #HIV drugs stop the virus after it is already inside the cell. A small molecule that stops it at the door is a different bet, and a harder one.
Viva-Thera, which we incubated, has nominated a preclinical candidate against that entry machinery in 7 months.
The target: MPER
Viva-Thera, which we incubated, has nominated a preclinical candidate against that entry machinery in 7 months.
The target: MPER
As AI gets better at proposing synthesis routes, how do we decide which ones deserve to reach the lab first—and learn from the ones we reject?
September 21, 2026 at 3:17 PM
As AI gets better at proposing synthesis routes, how do we decide which ones deserve to reach the lab first—and learn from the ones we reject?